Harmony Biosciences Holdings Inc Revenue Growth Rates (HRMY), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Harmony Biosciences Holdings inc   (NASDAQ: HRMY)
 

HRMY's Revenue Growth by Quarter and Year

Harmony Biosciences Holdings Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/HRMY/growth
https://api.csimarket.com/api/v1/companies/HRMY/fundamentals
https://api.csimarket.com/api/v1/companies/HRMY/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
HRMY Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 268.92
2nd Quarter June 261.28
1st Quarter March 214.88
FY 745.08

HRMYs Annual Revenue
Harmony Biosciences Holdings Inc 's Revenue in the fiscal year 2025 $ 868.11 millions
Harmony Biosciences Holdings Inc 's Revenue in the fiscal year 2024 $ 713.92 millions
Harmony Biosciences Holdings Inc 's Revenue in the fiscal year 2023 $ 581.79 millions
Harmony Biosciences Holdings Inc 's Revenue in the fiscal year 2022 $ 437.86 millions
Harmony Biosciences Holdings Inc 's Revenue in the fiscal year 2021 $ 305.44 millions




HRMY Revenue third quarter 2026 Y/Y Growth Comment
Harmony Biosciences Holdings inc reported Revenue increase of 12.61% year on year in the third quarter 2026, to $ 268.92 millions, this is lower than Harmony Biosciences Holdings Inc 's recent average Revenue improvement of 36.2%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 103 other companies have achieved higher Revenue growth. While Harmony Biosciences Holdings Inc ' s Revenue growth of 12.61% ranks overall at the positon no. 2184 in the third quarter 2026.


HRMY Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 12.61 %
2nd Quarter June 30.42 %
1st Quarter March 16.95 %
FY   -

Financial Statements
Harmony Biosciences Holdings Inc 's third quarter 2026 Revenue $ 268.92 millions HRMY's Income Statement
Harmony Biosciences Holdings Inc 's third quarter 2025 Revenue $ 238.81 millions Quarterly HRMY's Income Statement


HRMY Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 2.92 %
2nd Quarter June 21.59 %
1st Quarter March -12.38 %
FY (Year on Year)   -


Back to HRMY Growth rate Comparisons >> Back to HRMY Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #104
Healthcare Sector #323
Overall #2184

Revenue Y/Y Growth Statistics
High Average Low
91.21 % 36.2 % 17.7 %
(Dec 31 2021)   (Jun 30 2025)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #104
Healthcare Sector #323
Overall #2184
Revenue Y/Y Growth Statistics
High Average Low
91.21 % 36.2 % 17.7 %
(Dec 31 2021)   (Jun 30 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Harmony Biosciences Holdings Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
91.56 % 12.24 % -12.38 %
(Jun 30 2020)  


HRMY's III. Quarter Q/Q Revenue Comment
Harmony Biosciences Holdings inc achieved in the III. Quarter 2026 below company average Revenue growth of 2.92% quarter on quarter, to $ 268.92 millions.

Within Major Pharmaceutical Preparations industry 47 other companies have achieved higher Revenue quarter on quarter growth. While Harmony Biosciences Holdings Inc 's Revenue growth quarter on quarter, overall rank is 493.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #48
Healthcare Sector #98
Overall #493
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #48
Healthcare Sector #98
Overall #493
Revenue Q/Q Growth Statistics
High Average Low
91.56 % 12.24 % -12.38 %
(Jun 30 2020)  


HRMY's III. Quarter Q/Q Revenue Comment
Harmony Biosciences Holdings inc achieved in the III. Quarter 2026 below company average Revenue growth of 2.92% quarter on quarter, to $ 268.92 millions.

Within Major Pharmaceutical Preparations industry 47 other companies have achieved higher Revenue quarter on quarter growth. While Harmony Biosciences Holdings Inc 's Revenue growth quarter on quarter, overall rank is 493.


Harmony Biosciences Holdings Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 960.19
Y / Y Revenue Growth (TTM) 24.51 %
Year on Year Revenue Growth Overall Ranking # 947
Seqeuential Revenue Change (TTM) 6.78 %
Seq. Revenue Growth (TTM) Overall Ranking # 2227


Cumulative Revenue growth Comment
Although Harmony Biosciences Holdings Inc 's Annual Revenue growth year on year were below company's average 36.2% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 24.51% year on year, from 20.94% in Mar 31 2026.

In the Healthcare sector 183 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 440 to 947.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 105
Healthcare Sector # 184
Overall # 947

Revenue TTM Y/Y Growth Statistics
High Average Low
91.21 %
 36.2 %
17.7 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 105
Sector # 326
S&P 500 # 2227
Cumulative Revenue growth Comment
Although Harmony Biosciences Holdings Inc 's Annual Revenue growth year on year were below company's average 36.2% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 24.51% year on year, from 20.94% in Mar 31 2026.

In the Healthcare sector 183 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 440 to 947.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 105
Healthcare Sector # 184
Overall # 947

Revenue TTM Y/Y Growth Statistics
High Average Low
91.21 %
36.2 %
17.7 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 105
Sector # 326
S&P 500 # 2227




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
HRMY's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Alkermes Plc 21.80%$ 21.804 millions
Alpha Teknova Inc 21.52%$ 21.523 millions
Anteris Technologies Global Corp 20.98%$ 20.979 millions
Trisalus Life Sciences Inc 20.81%$ 20.807 millions
Orthopediatrics Corp20.55%$ 20.551 millions
Alpha Pro Tech Ltd 19.73%$ 19.729 millions
Insulet Corporation19.21%$ 19.213 millions
Abcellera Biologics Inc 18.81%$ 18.805 millions
Schrodinger Inc 18.72%$ 18.715 millions
Procept Biorobotics Corporation18.41%$ 18.414 millions
Supernus Pharmaceuticals inc 18.05%$ 18.047 millions
Outset Medical Inc 17.51%$ 17.510 millions
Alnylam Pharmaceuticals Inc 16.74%$ 16.738 millions
IMPACT BIOMEDICAL INC.16.67%$ 16.667 millions
Rigel Pharmaceuticals Inc16.45%$ 16.452 millions
Si bone inc 16.42%$ 16.424 millions
Ars Pharmaceuticals Inc 16.03%$ 16.027 millions
Atricure Inc 15.84%$ 15.839 millions
Ardelyx inc 15.70%$ 15.704 millions
Novocure Limited15.67%$ 15.666 millions
Penumbra Inc15.64%$ 15.636 millions
Orasure Technologies Inc15.45%$ 15.445 millions
Electromed Inc 15.34%$ 15.342 millions
Irhythm Holdings Inc 15.34%$ 15.339 millions
P3 Health Partners Inc 14.80%$ 14.798 millions
Msa Safety Inc14.72%$ 14.716 millions
Ensign Group Inc14.47%$ 14.471 millions
Abbott Laboratories14.46%$ 14.460 millions
Electrocore Inc 14.40%$ 14.404 millions
Allogene Therapeutics Inc 14.29%$ 14.286 millions


About Harmony Biosciences Holdings Inc Revenue Growth Rates (HRMY), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Harmony Biosciences Holdings Inc (CIK 1802665).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-122390
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Harmony Biosciences Holdings Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.